Léim ar aghaidh chuig an bpríomhábhar
Gnáthamharc

Thursday, 26 Feb 2026

Written Answers Nos. 531-559

Health Service Executive

Ceisteanna (531)

Ken O'Flynn

Ceist:

531. Deputy Ken O'Flynn asked the Minister for Health whether, in the exercise of its statutory oversight of the Health Service Executive under the Health Act 2004, receives or requests data on the single longest recorded ambulance response time for clinical status 1 purple and red calls in each month nationally and by HSE region; if not, whether she considers the absence of such governance reporting compatible with effective patient safety oversight; and whether she will direct that such data be formally reported to her Department. [15859/26]

Amharc ar fhreagra

Freagraí scríofa

As this is a service matter, it has been referred to the Health Service Executive for attention and direct reply to the Deputy.

Ambulance Service

Ceisteanna (532, 533, 537, 554, 556, 557)

Ken O'Flynn

Ceist:

532. Deputy Ken O'Flynn asked the Minister for Health whether it is Departmental policy that an ambulance response exceeding 60 minutes to a clinical status 1 purple or red emergency call does not, of itself, constitute a notifiable patient safety incident under the HSE Incident Management Framework; the policy basis for that position; and whether she will review that policy in the context of her statutory responsibility for patient safety and quality governance. [15860/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

533. Deputy Ken O'Flynn asked the Minister for Health whether her Department has, since 1 January 2023, received any aggregated report, briefing, risk register entry, or governance submission identifying delayed ambulance response as a contributory factor in patient harm or adverse outcomes; the number of such instances recorded; and whether her Department has conducted any formal policy review arising from those findings. [15861/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

537. Deputy Ken O'Flynn asked the Minister for Health whether her Department has issued any policy guidance defining the circumstances in which prolonged ambulance response times constitute patient safety incidents; whether delays exceeding 60 minutes in life-threatening emergencies are automatically reviewed under the HSE Incident Management Framework; and if not, the governance basis for excluding such delays from mandatory safety review. [15865/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

554. Deputy Ken O'Flynn asked the Minister for Health whether the current National Ambulance Service key performance Indicator (KPI) framework, including the absence of any maximum response time thresholds for clinical status 1 purple and red calls, has been formally approved, endorsed or noted by her Department; the date on which the current KPI framework was last reviewed by her Department; and whether any review of the scope of those KPIs is currently underway. [15889/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

556. Deputy Ken O'Flynn asked the Minister for Health whether the Department of Health Enterprise Risk Management Framework identifies prolonged ambulance response times for life-threatening emergencies as a strategic or operational risk; if so, the risk rating currently assigned; and if not, whether she will require that this risk be formally assessed and recorded. [15891/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

557. Deputy Ken O'Flynn asked the Minister for Health whether any internal Departmental briefings, submissions, memoranda or governance reviews since 2020 have considered the question of whether emergency ambulance response times exceeding 60 minutes should be classified or recorded as patient safety incidents; and if so, to outline the conclusions reached. [15892/26]

Amharc ar fhreagra

Freagraí scríofa

I propose to take Questions Nos. 532, 533, 537, 554, 555, 556 and 557 together.

I refer the Deputy to the answer I gave to Question 580 on 12 February. Each year, the Health Service Executive's (HSE) National Service Plan (NSP) outlines the overarching goals across all of its operational areas. Within these goals specific draft Key Performance Indicators (KPI) targets are set out, which the HSE then agrees with my Department before the NSP is finalised and published. Outside of the published KPIs the HSE maintains additional data which is used for the ongoing review of operational areas, including National Ambulance Service (NAS) performance and resourcing and such information is presented and considered by my Department including within the margins of the annual estimates process.

As I made clear in my reply to Question 580, there are well established procedures in place, under which the HSE informs my Department of all major or significant patient or service user safety incidents and issues of concern across the HSE. This includes the HSE’s Incident Management Framework which is applied to the management of individual incidents and is also the mechanism for incident reviews in the HSE. As the Deputy will be aware from my earlier answers, the HSE reports into my Department on a monthly basis on its performance against NSP KPIs and the performance results form the basis of ongoing engagement between my Department and the HSE throughout the year, with certain key performance areas escalated for attention where appropriate with a view toward achieving improvements.

In relation to risk, my Department holds a quarterly Risk Management meeting with the HSE to discuss strategic and high-rated risks and the operation of the HSE Risk Register.

Taken together these meetings help to ensure that the Department ensures that top level management in the HSE and the HSE Board are accountable to appropriate high standards in managing the delivery of all healthcare services.

Question No. 533 answered with Question No. 532.

Ambulance Service

Ceisteanna (534, 536, 538, 539, 540, 541, 542, 544, 545, 546, 558, 559)

Ken O'Flynn

Ceist:

534. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives regional disaggregated performance data for clinical status 1 purple and red emergency calls as part of the annual Service Plan governance framework; whether her Department undertakes structured comparative analysis of response performance between HSE regions; and the specific policy directives issued by her since 2023 to address identified regional inequities in emergency ambulance response times. [15862/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

536. Deputy Ken O'Flynn asked the Minister for Health whether the National Ambulance Service records the number of clinical status 1 Purple and Red emergency calls where the response time exceeds 30 minutes, 45 minutes, and 60 minutes; if so, to provide the total number in each category for each of the past three years; and if not, the policy rationale for not capturing such data within the State’s emergency performance framework. [15864/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

538. Deputy Ken O'Flynn asked the Minister for Health the approved whole-time equivalent staffing target for the National Ambulance Service for each year 2023 to 2026 under the NAS Workforce Plan; the actual WTE achieved in each year; the variance between target and actual; and the measures being taken to close the current capacity deficit (details supplied); and if she will make a statement on the matter. [15866/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

539. Deputy Ken O'Flynn asked the Minister for Health whether her Department conducts formal comparative analysis of ambulance response performance between HSE regions; whether any equity standard exists to ensure consistent life-threatening emergency response across regions; and the corrective mechanisms triggered where sustained regional underperformance is identified. [15867/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

540. Deputy Ken O'Flynn asked the Minister for Health how long the National Ambulance Service has operated above NASCAP Level 1 since 2022; the total number of days spent at Levels 2 and 3 in each of the past three years; and whether the Department considers a prolonged state of escalation compatible with stable emergency service governance. [15868/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

541. Deputy Ken O'Flynn asked the Minister for Health whether a national policy exists within the National Ambulance Service requiring that a life-threatening emergency call be allocated to the next available ambulance within a fixed time window, including a 90-second allocation protocol; when this policy was introduced; the clinical or operational rationale underpinning it; and whether she has reviewed its impact on resource efficiency and regional coverage. [15871/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

542. Deputy Ken O'Flynn asked the Minister for Health the number of occasions in each of the past three years where an ambulance assigned to a life-threatening emergency call was dispatched from outside the county in which the incident occurred; the average travel distance and time in such cases; and whether her Department has assessed the impact of long-distance dispatch on local ambulance availability. [15872/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

544. Deputy Ken O'Flynn asked the Minister for Health whether her Department or HSE has undertaken any cost-benefit or efficiency analysis of the current national dispatch model, including fuel expenditure, crew time utilisation, overtime costs, and opportunity cost arising from cross-regional dispatch and stand-down; and if so, to provide details. [15878/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

545. Deputy Ken O'Flynn asked the Minister for Health whether any formal clinical risk assessment has been conducted in relation to the National Ambulance Service dispatch model where units are assigned across regions under a time-based allocation protocol; whether this model has been benchmarked against alternative international dispatch systems; and whether any review is planned. [15875/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

546. Deputy Ken O'Flynn asked the Minister for Health whether her Department monitors instances where rural or peripheral areas are temporarily left without local ambulance cover due to cross-regional dispatch under national allocation protocols; the frequency of such occurrences in the past three years; and the safeguards in place to mitigate exposure risk in those areas. [15876/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

558. Deputy Ken O'Flynn asked the Minister for Health the number of occasions in 2025 on which the National Ambulance Service operated at NASCAP level 3; the duration in days of each such period; whether any escalation to level 4 was considered; and the formal reporting mechanism by which such escalation levels are notified to her Department. [15893/26]

Amharc ar fhreagra

Ken O'Flynn

Ceist:

559. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken or commissioned any comparative review of international ambulance service performance governance frameworks, including the use of outlier response time reporting, since 2018; and if so, to provide the title and date of such review and the principal findings. [15894/26]

Amharc ar fhreagra

Freagraí scríofa

I propose to take Questions Nos. 534, 536, 538, 539, 540, 541, 542, 544, 545, 546, 558 and 559 together.

I have asked the Health Service Executive (HSE) to respond directly to the Deputy as soon as possible with any pertinent information that it may have in regard to the specific requests for data raised in his questions.

As outlined in my response to Question 580 on 12 February, my Department remains committed to increasing investment in the National Ambulance Service (NAS) to grow service capacity to meet the continuous increase in patient demand. Between 2020 and 2025 funding for the NAS has increased by over 60% and has helped to provide for a growth in staffing of nearly 30%, of which over 85% work in direct patient facing roles.

In 2026, the HSE has approved 263 posts to help further strengthen ambulance frontline emergency response capacity, intermediate care services and alternative care pathways, as well as provide for the establishment of a new Helicopter Emergency Medical Service (HEMS) serving the West and North-West of the country.

As outlined previously to the Deputy, each year the Health Service Executive's (HSE) National Service Plan (NSP) outlines the overarching goals across all of its operational areas. Within these goals specific draft Key Performance Indicators (KPI) targets are set out, which the HSE then agrees with my Department before the NSP is finalised and published.

Outside of the published KPIs the HSE maintains additional data which is used for the ongoing review of operational areas, including National Ambulance Service (NAS) performance and resourcing and such information is presented and considered by my Department including within the margins of the annual estimates process.

As the Deputy will be aware from my earlier answers, the HSE reports into my Department on a monthly basis on its performance against NSP KPIs and the performance results form the basis of ongoing engagement between my Department and the HSE throughout the year, with certain key performance areas escalated for attention where appropriate with a view toward achieving improvements.

Ambulance Service

Ceisteanna (535)

Ken O'Flynn

Ceist:

535. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has undertaken any analysis of mortality, morbidity, or adverse clinical outcomes for clinical status 1 Purple or Red emergency calls stratified by response time bands (0–19 minutes, 20–30 minutes, 31–45 minutes, 46–60 minutes, and over 60 minutes) during the period 2023 to date; if so, to provide details of the findings; and if not, whether she will direct that such outcome-based analysis be conducted and published. [15863/26]

Amharc ar fhreagra

Freagraí scríofa

As this is a service matter, it has been referred to the Health Service Executive for attention and direct reply to the Deputy.

Question No. 536 answered with Question No. 534.
Question No. 537 answered with Question No. 532.
Question No. 538 answered with Question No. 534.
Question No. 539 answered with Question No. 534.
Question No. 540 answered with Question No. 534.
Question No. 541 answered with Question No. 534.
Question No. 542 answered with Question No. 534.

Ambulance Service

Ceisteanna (543)

Ken O'Flynn

Ceist:

543. Deputy Ken O'Flynn asked the Minister for Health the number of instances in each of the past three years where an ambulance dispatched to a life-threatening emergency call travelled more than 20 minutes, 30 minutes, or 45 minutes before being stood down due to reassignment; whether such redeployments are reviewed for resource efficiency and patient safety impact; and whether national guidelines exist governing maximum travel before stand-down. [15873/26]

Amharc ar fhreagra

Freagraí scríofa

As this is a service matter, it has been referred to the Health Service Executive for attention and direct reply to the Deputy.

Question No. 544 answered with Question No. 534.
Question No. 545 answered with Question No. 534.
Question No. 546 answered with Question No. 534.

Ambulance Service

Ceisteanna (547)

Ken O'Flynn

Ceist:

547. Deputy Ken O'Flynn asked the Minister for Health whether the 90-second allocation protocol forms part of the HSE Enterprise Risk Register; whether it has been subject to independent audit or review since 2020; and whether she is satisfied that the current dispatch framework balances speed of allocation with geographic efficiency and sustained regional capacity. [15877/26]

Amharc ar fhreagra

Freagraí scríofa

As this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.

Medicinal Products

Ceisteanna (548)

Ken O'Flynn

Ceist:

548. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 315 of 11 February 2025, and noting that the National Centre for Pharmacoeconomics completed a full health technology assessment of tirzepatide for the treatment of adults with insufficiently controlled type 2 diabetes mellitus on 9 February 2026, and for weight management on 3 December 2025, whether she has been notified of the completion of those assessments; the month in 2026 in which the HSE senior leadership team is scheduled to consider each application for pricing and reimbursement; whether any internal target decision date has been set by her Department or the HSE; and if she will make a statement on the matter. [15874/26]

Amharc ar fhreagra

Freagraí scríofa

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has sole statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Medicinal Products

Ceisteanna (549)

Ken O'Flynn

Ceist:

549. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has prepared or received any gross and net budget impact analysis in respect of the proposed reimbursement of tirzepatide and semaglutide for diabetes and weight management indications; the estimated annual gross cost to the Exchequer in each of the first five years of potential reimbursement; any estimated downstream cost offsets relating to reduced incidence of type 2 diabetes complications, cardiovascular disease or renal failure; and whether specific provision has been made within Vote 38 for 2026 to accommodate any such reimbursement decision. [15879/26]

Amharc ar fhreagra

Freagraí scríofa

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Medicinal Products

Ceisteanna (550)

Ken O'Flynn

Ceist:

550. Deputy Ken O'Flynn asked the Minister for Health the estimated number of adults nationally who meet the clinical eligibility thresholds outlined in the completed HTAs for tirzepatide for diabetes and weight management indications; the estimated number of adolescents who would meet the subpopulation criteria proposed for semaglutide reimbursement; whether her Department has been advised of projected uptake rates; and if she will make a statement on the matter. [15880/26]

Amharc ar fhreagra

Freagraí scríofa

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Medicinal Products

Ceisteanna (551)

Ken O'Flynn

Ceist:

551. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken any comparative assessment of the timeframe from marketing authorisation to reimbursement decision for GLP-1 receptor agonists in Ireland relative to other EU Member States; whether she considers the current pharmacoeconomic assessment and negotiation timeline proportionate to the scale of the public health burden posed by obesity and type 2 diabetes; and if she will make a statement on the matter. [15881/26]

Amharc ar fhreagra

Freagraí scríofa

Once a company responsible for the commercialisation of a new medicine receives marketing authorisation from the European Medicines Agency (EMA), it can apply for reimbursement in the country (or countries) of its choice.

The timing of company applications for new medicines reimbursement in different countries can vary for several reasons, not least the available market share in each country.

Ireland, by virtue of its size and market share, may not always be prioritised by a company in the first stages of marketing a new product. The reimbursement assessment process cannot begin until an application is received. The HSE cannot decide to reimburse a new medicine if no application is received from a company.

Access to medicines requires industry and the State to work together, through timely assessment, and reasonable pricing with fully completed HTAs (Health Technology Assessments).

Pharmaceutical firms are encouraged to proactively engage with the HSE, to submit application dossiers that contain the information needed by the National Centre for Pharmacoeconomics (NCPE) to undertake the required assessments as efficiently as possible on behalf of the State.

Medicinal Products

Ceisteanna (552)

Ken O'Flynn

Ceist:

552. Deputy Ken O'Flynn asked the Minister for Health whether formal commercial negotiations between the HSE Corporate Pharmaceutical Unit and the relevant marketing authorisation holders in respect of tirzepatide and semaglutide are currently active; whether any price proposal has been received following completion of the HTA processes; whether any budget ceiling or access cap has been set as a matter of Departmental policy; and if she will make a statement on the matter. [15882/26]

Amharc ar fhreagra

Freagraí scríofa

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has sole statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Ambulance Service

Ceisteanna (553)

Ken O'Flynn

Ceist:

553. Deputy Ken O'Flynn asked the Minister for Health whether her Department has approved, directed, agreed to, or otherwise authorised any performance reporting methodology under the Health Service Executive National Service Plan whereby clinical status 1 purple or red emergency ambulance calls with response times exceeding 60 minutes are excluded, truncated, capped, or otherwise omitted from published National Ambulance Service key performance indicators; if so, to state the date on which such methodology was adopted, the approving authority within her Department, the governance or policy document under which it operates, and whether she is satisfied that such an approach provides full transparency in respect of life-threatening emergency response performance; and if no such methodology exists, to confirm explicitly that all clinical status 1 purple and red calls, irrespective of response duration, are included in the denominator of published performance indicators and to outline the publication methodology applied. [15888/26]

Amharc ar fhreagra

Freagraí scríofa

As this is a service matter, I have asked the Health Service Executive to respond to the deputy directly, as soon as possible.

Question No. 554 answered with Question No. 532.
Question No. 555 answered with Question No. 532.
Question No. 556 answered with Question No. 532.
Question No. 557 answered with Question No. 532.
Question No. 558 answered with Question No. 534.
Question No. 559 answered with Question No. 534.
Roinn